APPLICATIONS PUBLISHED 11 AUGUST 2004
Published: 1-Feb-2005
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Product containing a red alga extract of the genus porphyria and uses thereof for protecting cells
Larena 1443898*
Bowel cleansing agent
Shimizu Pharmaceutical 1443899*
Lipid carrier compsns with enhanced blood stability
Celator Technologies 1443900*
Soluble drug extended release system
Yamanouchi Pharma Technologies; Yamanouchi Pharmaceutical 1443901*
Method of producing stable solutions of phenolic substances and resulting solutions
Laboratoires Aguettant 1443902*
Proliposomal drug delivery system
Western Center for Drug Development 1443903*
Orally administered pharmaceutical preparation comprising liposomally encapsulated paclitaxel
Max-Delbrueck-Centrum fuer Molekulare Medizin 1443904*
Compsns for oral gene therapy and methods of using the same
The Johns Hopkins University 1443905*
Method for the formulation of ibuprofen crystals
BASF 1443906*
Biocompatible polymer blends and uses thereof
Alkermes Controlled Therapeutics 1443907*
Nanostructured compsns
Nanophase Technologies Corp 1443908*
Process for preparing dry extracts
Finzelberg 1443909*
Controlled release compsns for macrolide antimicrobial agents
Wockhardt 1443910*
Process for preparing quick dissolving, high loading ribavirin compsns
Geneva Pharmaceuticals 1443911*
Compsns having a combination of immediate release and controlled release characteristics
Elan Pharma 1443912*
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
Curagen 1443913*
Method and pharmaceutical preparations for reducing the activity of cells
Lycored Natural Products Industries 1443914*
Pharmaceutical and cosmetic compsns containing oxy group-bearing aromatic aldehydes
Cutanix 1443915*
Pharmaceutical compsn comprising an adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor
Aventis Pharmaceuticals 1443916*
Tamsulosin tablets
Synthon 1443917*
Calcium-L-threonate for preventing or treating bone fracture
Juneng Industry 1443918*
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
Bristol-Myers Squibb 1443919*
Preparation for improving the action of receptors
NV Nutrica 1443920*
Production of pure stereoisomers of tricyclo 5.2.1.0 SP 2.6/SP -dec-9-yl-xanthogenate and medicaments therefrom
BioSphings 1443921*
MCH antagonists for the treatment of obesity
Schering 1443922*
Hydroxy substituted amides for the treatment of Alzheimer's disease
Elan Pharmaceuticals 1443923*
4-(3,5-bis-(2-hydroxy-phenyl)-[1,2,4-triazol-1-yl)-benzoic acid derivatives for treating an excess of metal in the body
Novartis 1443924*
Naphthyridine derivative, their preparation and use as phophodiesterase isoenzyme 4 (PDE4) inhibitors
Novartis 1443925*
Pyridine derivatives as NMDA-receptor subtype blockers
F Hoffmann-La Roche 1443926*
Carboline derivatives as inhibitors of IKB in treatment of multiple myeloma and other cancers
Millennium Pharmaceuticals 1443927*
Treatment of neurodegenerative diseases and cancer of the brain
Sloan-Kettering Institute for Cancer Research 1443928*
Treatment of CNS disorders using CNS target modulators
Hypnion 1443929*
Isoxazoline derivatives useful as antimicrobials
AstraZeneca 1443930*
Methods for treating neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments
Iomed 1443931*
Pharmaceutical compsns containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
Micro Algae Corp 1443932*
Treatment of chronic myelogenous leukaemia, resistant or intolerant to STI571, involving homoharringtonine alone or combined with other agents
Stragen Pharma 1443933*
Benzotriazepines as gastrin and cholecystokinin receptor ligands
James Black Foundation 1443934*
Treatment of infectious disease using interleukin-1 beta converting enzyme (ICE)/CED-3 family inhibitors
Idun Pharmaceuticals 1443935*
Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
Bristol-Myers Squib 1443936*
Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
3-Dimensional Pharmaceuticals 1443937*
Dosage unit comprising a prostaglandin analogue for treating constipation
Sucampo 1443938*
Compsns for treatment of post-menopausal female sexual dysfunction
Pharmacia 1443939*
Pharmaceutical compsn based on micronised progesterone, preparation method and uses thereof
Besins International Belgique 1443940*
Agents for treating lesions of the nervous system
Mex-Delbrueck-Centrum fuer Molekulare Medizin 1443941*
Pharmaceutical compsn for use for the treatment of malignancies comprising in combination a bisphosphonate, a COX-2 inhibitor and a taxol
Novartis 1443942*
Process for reacting alkaloids and use of the reaction products in the preparation of medicaments
Nowicky, Wassyl 1443943*
